

Room	Live Streaming		
Japan Time			
16:00			
0			
10			
20			
30			
40			
50			
17:00			
0			
10			
20			
30			
40			
50			
18:00			
0			
10			
20			
30			
40			
50			
19:00			
0			
10			
20			
30			
40			
50			
20:00			
0			
10			
20			
30			
40			
50			
21:00			
0			
10			
20			
30			

17:00-20:30
ISA 2021 Pediatric
Familial
Hypercholesterolemi
a Satellite
Symposium
 The Dawn of a New
 Era for Screening,
 Diagnosis and
 Treatments for
 Pediatric FH

Room	Room 1 + Live Streaming	Room 2 + Live Streaming	Room 3 + Live Streaming
Japan Time	Annex 1	Room A	Room D
7:00	<p>The 53rd Annual Scientific Meeting of the Japan Atherosclerosis Society</p>		
10			
20			
30			
40			
50			
8:00			
10			
20			
30			
40			
50			
9:00			
10			
20			
30			
40			
50			
10:00			
10			
20			
30			
40			
50			
11:00			
10			
20			
30			
40			
50			
12:00			
10			
20			
30			
40			
50			
13:00			
10			
20			
30			
40			
50			
14:00			
10			
20			
30			
40			
50			
15:00			
10			
20			
30			
40			
50			
16:00			
10			
20			
30			
40			
50			
17:00			
10			
20			
30			
40			
50			
18:00			
10			
20			
30			
40			
50			
19:00			
10			
20			
30			
40			
50			

Room	Room 1 + Live Streaming	Room 2 + Live Streaming	Room 3 + Live Streaming
Japan Time	Annex 1	Room A	Room B-1
7:00			
7:10			
7:20			
7:30			
7:40	7:30-8:30		
7:50	Morning Seminar 1		
8:00	MOCHIDA PHARMACEUTICAL		
8:10	Comprehensive lipid management in		
8:20	Coronary Artery Disease with highly		
8:30	purified EPA		
8:40			
8:50			
9:00			
9:10	8 : 40-10 : 10	8 : 40-10 : 10	8 : 40-10 : 10
9:20	Symposium 1	Symposium 2	Symposium 3
9:30	Lipid:	Diabetes:	Obesity, Metabolic
9:40	Awareness of FH	New Horizon for Basic	Syndrome
9:50		Research on Diabetic	
10:00		Complications	
10:10			
10:20			
10:30			
10:40	10:15-11:45	10:15-11:45	10:15-11:45
10:50	Symposium 4	Plenary Symposium1	Symposium 5
11:00	COVID-19:	Hypertension/kidney disease	NASH: NAFLD/NASH and
11:10	COVID-19 pandemic	- Systemic Hemodynamic	Cardiovascular Diseases
11:20	impact on cardiovascular	Atherothrombotic Syndrome and	
11:30	diseases	Resonance Hypothesis of Blood	
11:40		Pressure Variability: Triggering	
11:50		Cardiovascular Events	
12:00			
12:10	11:50-12:50	11:50-12:50	
12:20	Luncheon Seminar1	Luncheon Seminar2	
12:30	Takeda Pharmaceutical	Novartis Pharma K.K.	
12:40	Company Limited	Management of cardiovascular risk	
12:50	Roles of Triglyceride in Residual	by comprehensive risk approach	
13:00	Risk of Cardiovascular Events	especially from	
13:10		the cardiologist point of view	
13:20			
13:30			
13:40			
13:50			
14:00			
14:10	13 : 15-14 : 45	13 : 00-15 : 00	13 : 15-14 : 45
14:20	Symposium 6	APSAVD-IAS-JAS Joint	Symposium 7
14:30	"Hypertension"	Symposium	Aging: Public and patient
14:40	Management of	Evidence of triglyceride-rich	education to prevent
14:50	Cardiovascular Diseases by	lipoproteins and remnant	atherosclerotic diseases in
15:00	Mineralocorticoid Receptor	cholesterol for residual	Asia
15:10	Antagonist: Above and	cardiovascular risk	
15:20	Beyond	management.	
15:30			
15:40			
15:50			
16:00			
16:10	15:05-15:55	15:05-15:55	15:05-15:55
16:20	Moderated Session	Moderated Session	Moderated Session
16:30			
16:40	ISA2021 YIA	Dyslipidemia	Pathogenesis
16:50	Winners Session		
17:00			
17:10			
17:20			
17:30			
17:40			
17:50			
18:00			
18:10	16:00-17:30	16:00-17:30	16:00-17:30
18:20	Symposium 8	IAS/EAS/NLA/JAS Joint	Symposium 9
18:30	Diabetes	Guidline	Aging: Basic
18:40			
18:50			
19:00			
19:10			
19:20			
19:30			
19:40			
19:50			

Room	Room 1 + Live Streaming	Room 2 + Live Streaming	Room 3 + Live Streaming
Japan Time	Annex 1	Room A	Room B-1
7:00			
7:10			
7:20			
7:30			
7:40			
7:50			
8:00	7:45-9:15 Prenary Symposium4 Lipid- HDL and Reverse Cholesterol Transport -Prospect for antiatherogenic agent associated with HDL metabolism-	7:45-9:15 Symposium10 Diet Pattern and CVD	
8:10			
8:20			
8:30			
8:40			
8:50			
9:00			
9:10			
9:20			
9:30			
9:40			
9:50			
10:00	9 : 20-10 : 50 Symposium11 Cutting edge science in vascular biology	9 : 20-10 : 50 Symposium12 Lipid: Recent progress in apolipoprotein research	9 : 20-10 : 50 Symposium13 Innovation: Clinical Impacts of Innovative New Drugs and Therapeutics: Evidences vs. Real World
10:10			
10:20			
10:30			
10:40			
10:50			
11:00			
11:10			
11:20			
11:30			
11:40			
11:50			
12:00	11:00-12:30 Symposium14 Lipid: Atherosclerotic lesions - Smooth Muscle cells, Macrophages and ECM	11 : 00-12 : 30 Symposium15 Gender & Atherosclerosis	11 : 00-12 : 30 Symposium16 Thrombosis: Thrombotic and hemorrhagic disorders
12:10			
12:20			
12:30			
12:40			
12:50			
13:00	12 : 40-13 : 40 Luncheon Seminar 3 Nippon Boehringer Ingelheim/ Eli Lilly Japan Four practical approaches to reduce cardiovascular diseases in diabetic patients	12 : 40-13 : 40 Luncheon Seminar 4 Sysmex Corporation Current Status and Future Perspective of HDL Functions	
13:10			
13:20			
13:30			
13:40			
13:50			
14:00			
14:10			
14:20			
14:30			
14:40			
14:50			
15:00	13 : 50-15 : 20 Symposium17 Diabetes: Current Clinical Evidence on Prevention of Diabetic Complications	13 : 50-15 : 20 Symposium18 Cardiovascular disease/Thrombosis: Updated of Pharmacological Therapy for Hyperlipidemia	13 : 50-15 : 20 KSoLA-JAS Joint Symposium Epigenomic Control of Immuno-Fat Metabolism in Obesity and Cardiovascular Disease
15:10			
15:20			
15:30			
15:40			
15:50			
16:00	15:30-16:20 Moderated Session Epidemiology	15:30-16:20 Moderated Session Prevention	15:30-16:20 Moderated Session Therapeutics
16:10			
16:20			
16:30			
16:40			
16:50			
17:00	16 : 30-18 : 00 Sponsored Session Kowa Company Growing knowledge and future perspectives on residual risk from remnants	16 : 30-18 : 00 Symposium19 HDL: Recent progress in apolipoprotein research	16 : 30-18 : 00 Symposium20 Hypertension/kidney disease: Kidney Disease: CKD and Anemia; HIF and Iron
17:10			
17:20			
17:30			
17:40			
17:50			
18:00			
18:10			
18:20			
18:30			
18:40			
18:50			
19:00	18 : 10-19 : 40 Plenary Symposium5 Epidemiology - New Era of Pharmacological Therapy for Coronary Artery Disease	18 : 10-19 : 40 Symposium21 Lipoprotein (a) from Biology to Therapy	18:10-19:00 Moderated Session IAS Asia Pacific YIA Winners Session
19:10			
19:20			
19:30			
19:40			
19:50			
20:00	18:50-19:20 Special Session Yuji Matsuzawa		
20:10			
20:20			
20:30			
20:40			
20:50			

Room	Room 1 + Live Streaming	Room 2 + Live Streaming	Room 3 + Live Streaming
Japan Time	Annex 1	Room A	Room B-1
7:00			
10			
20			
30			
40	7:30-8:30 Morning Seminar 2 AstraZeneca.KK SGLT2i, GLP-1RA and Obesity treatments		
50			
8:00			
10			
20			
30			
40	8:40-10:10 Symposium 22 Omics approach toward understanding atherosclerosis	8:40-10:10 Symposium 23 Cancer & Atherosclerosis	8:40-10:10 Symposium 24 Atherosclerosis as a chronic inflammation
50			
9:00			
10			
20			
30			
40	10:20-11:50 Symposium 25 Imaging/Device: Development of Noninvasive Atherosclerotic Imaging	10:20-11:50 Symposium 26 Lipid: Bioactive phospholipid and fatty acids	10:20-11:50 Symposium 27 Nutrition: Dietary pattern and lipids
50			
10:00			
10			
20			
30			
40			
50			
11:00			
10			
20			
30			
40			
50			
12:00			
10	12:00-13:00 Luncheon Seminar 5 Takeda Pharmaceutical Company Intervention for hypertriglyceridemia to combat residual risk for cardiovascular disease	12:00-13:00 Luncheon Seminar 6 Amgen / Astellas Pharma Familial hypercholesterolemia and PCSK9 inhibitor	12:00-13:00 Luncheon Seminar 7 Novartis Pharma The importance of management of cardiovascular risk factors
20			
30			
40			
50			
13:00			
10	13:10-14:40 Symposium 28 Imaging/Device: Vulnerable Plaques and Intravascular Imaging	13:10-14:40 Symposium 29 Hypertension/ kidney disease: Hypertension: Vascular stiffness and cardiovascular outcome	13:10-14:40 KSoLA-JAS Joint Symposium Hypertriglyceridemia, Approach to the Residual Risk
20			
30			
40			
50			
14:00			
10			
20			
30			
40			
50			
15:00			
10	14:50-16:20 Symposium 30 Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease	14:50-16:10 Symposium 31 Epidemiology Big Data: Epidemiology for Atherosclerotic diseases in Asian Populations: history and Future direction	14:50-15:50 OSLA-IAS-JAS Joint Symposium Gender Differences in the Prevalence and Management of Atherosclerotic Cardiovascular Diseases: International Prospective
20			
30			
40			
50			
16:00			
10			
20			
30			
40	16:30-18:00 Plenary Symposium 6 Lipid - Cholesterol homeostasis	16:30-18:00 Plenary Symposium 7 Epidemiology Big Data - Big data analysis for adequate decision making to prevent atherosclerotic diseases	16:30-18:00 Symposium 32 Stroke: Lipid management for stroke prevention
50			
17:00			
10			
20			
30			
40			
50			
18:00			
10	18:10-19:40 Symposium 33 Stroke: novel therapeutic approach for stroke	18:10-19:40 Symposium 34 Imaging/Device: Optimal Management of High-risk Percutaneous Coronary Intervention	18:10-19:40 Symposium 35 Pediatric: Familial Hypercholesterolemia (FH) in Children and Young Adults
20			
30			
40			
50			
19:00			
10			
20			
30			
40			
50			